Literature DB >> 21463128

Response of hairy cell leukemia to bendamustine.

Robert J Kreitman, Evgeny Arons, Maryalice Stetler-Stevenson, Kenneth B Miller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21463128      PMCID： PMC7437359          DOI： 10.3109/10428194.2011.562575

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  14 in total

1.  Leukemic reticuloendotheliosis.

Authors:  B A BOURONCLE; B K WISEMAN; C A DOAN
Journal:  Blood       Date:  1958-07       Impact factor: 22.113

2.  Variables affecting the quantitation of CD22 in neoplastic B cells.

Authors:  Gregory A Jasper; Indu Arun; David Venzon; Robert J Kreitman; Alan S Wayne; Constance M Yuan; Gerald E Marti; Maryalice Stetler-Stevenson
Journal:  Cytometry B Clin Cytom       Date:  2010-09-24       Impact factor: 3.058

3.  Eradication of minimal residual disease in hairy cell leukemia.

Authors:  Farhad Ravandi; Jeffrey L Jorgensen; Susan M O'Brien; Srdan Verstovsek; Charles A Koller; Stefan Faderl; Francis J Giles; Alessandra Ferrajoli; William G Wierda; Shirley Odinga; Xuelin Huang; Deborah A Thomas; Emil J Freireich; Dan Jones; Michael J Keating; Hagop M Kantarjian
Journal:  Blood       Date:  2006-02-23       Impact factor: 22.113

4.  Long-term follow-up of patients with hairy cell leukemia after cladribine treatment.

Authors:  A Saven; C Burian; J A Koziol; L D Piro
Journal:  Blood       Date:  1998-09-15       Impact factor: 22.113

5.  Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia.

Authors:  Jorge Nieva; Kelly Bethel; Alan Saven
Journal:  Blood       Date:  2003-03-27       Impact factor: 22.113

6.  Soluble CD22 as a tumor marker for hairy cell leukemia.

Authors:  Kakushi Matsushita; Inger Margulies; Masanori Onda; Satoshi Nagata; Maryalice Stetler-Stevenson; Robert J Kreitman
Journal:  Blood       Date:  2008-07-02       Impact factor: 22.113

7.  Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.

Authors:  Monica Else; Claire E Dearden; Estella Matutes; Juan Garcia-Talavera; Ama Z S Rohatiner; Steve A N Johnson; Nigel T J O'Connor; Andy Haynes; Nnenna Osuji; Francesco Forconi; Francesco Lauria; Daniel Catovsky
Journal:  Br J Haematol       Date:  2009-03-29       Impact factor: 6.998

8.  Hairy cell leukemia: a clinical review based on 71 cases.

Authors:  H M Golomb; D Catovsky; D W Golde
Journal:  Ann Intern Med       Date:  1978-11       Impact factor: 25.391

9.  VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.

Authors:  Evgeny Arons; Tara Suntum; Maryalice Stetler-Stevenson; Robert J Kreitman
Journal:  Blood       Date:  2009-09-10       Impact factor: 22.113

10.  Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.

Authors:  Robert J Kreitman; Maryalice Stetler-Stevenson; Inger Margulies; Pierre Noel; David J P Fitzgerald; Wyndham H Wilson; Ira Pastan
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544
View more
  5 in total

Review 1.  Immunoconjugates and new molecular targets in hairy cell leukemia.

Authors:  Robert J Kreitman
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

2.  My treatment approach to hairy cell leukemia.

Authors:  Rahul R Naik; Alan Saven
Journal:  Mayo Clin Proc       Date:  2012-01       Impact factor: 7.616

3.  Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.

Authors:  Mauricio Burotto; Maryalice Stetler-Stevenson; Evgeny Arons; Hong Zhou; Wyndham Wilson; Robert J Kreitman
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

Review 4.  Update on the biology and treatment options for hairy cell leukemia.

Authors:  Preetesh Jain; Naveen Pemmaraju; Farhad Ravandi
Journal:  Curr Treat Options Oncol       Date:  2014-06

5.  Hairy cell leukemia: short review, today's recommendations and outlook.

Authors:  V Maevis; U Mey; G Schmidt-Wolf; I G H Schmidt-Wolf
Journal:  Blood Cancer J       Date:  2014-02-14       Impact factor: 11.037
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.